Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial.
Alemany A, Millat-Martinez P, Corbacho-Monné M, Malchair P, Ouchi D, Ruiz-Comellas A, Ramírez-Morros A, Rodríguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila-Jáuregui M, Torrano-Soler P, San José A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia Garcia V, Vidal-Alaball J, Millan A, Contreras E, Grifols JR, Ancochea À, Galvan-Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farré M, Pradenas E, Blanco J, Àngel Rodriguez-Arias M, Fernández Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitjà O; CONV-ERT Group. Alemany A, et al. Among authors: pradenas e. Lancet Respir Med. 2022 Mar;10(3):278-288. doi: 10.1016/S2213-2600(21)00545-2. Epub 2022 Feb 9. Lancet Respir Med. 2022. PMID: 35150610 Free PMC article. Clinical Trial.
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.
Díez JM, Romero C, Cruz M, Vandeberg P, Merritt WK, Pradenas E, Trinité B, Blanco J, Clotet B, Willis T, Gajardo R. Díez JM, et al. Among authors: pradenas e. J Infect Dis. 2022 Mar 15;225(6):938-946. doi: 10.1093/infdis/jiab540. J Infect Dis. 2022. PMID: 34693968 Free PMC article.
Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.
Pradenas E, Ubals M, Urrea V, Suñer C, Trinité B, Riveira-Muñoz E, Marfil S, Ávila-Nieto C, Rodríguez de la Concepción ML, Tarrés-Freixas F, Laporte J, Ballana E, Carrillo J, Clotet B, Mitjà O, Blanco J. Pradenas E, et al. Front Immunol. 2022 Apr 28;13:860215. doi: 10.3389/fimmu.2022.860215. eCollection 2022. Front Immunol. 2022. PMID: 35572570 Free PMC article.
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes.
Pradenas E, Trinité B, Urrea V, Marfil S, Ávila-Nieto C, Rodríguez de la Concepción ML, Tarrés-Freixas F, Pérez-Yanes S, Rovirosa C, Ainsua-Enrich E, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Paredes R, Mateu L, Chamorro A, Massanella M, Carrillo J, Clotet B, Blanco J. Pradenas E, et al. Med. 2021 Mar 12;2(3):313-320.e4. doi: 10.1016/j.medj.2021.01.005. Epub 2021 Jan 31. Med. 2021. PMID: 33554155 Free PMC article.
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
Abella E, Trigueros M, Pradenas E, Muñoz-Lopez F, Garcia-Pallarols F, Ben Azaiz Ben Lahsen R, Trinité B, Urrea V, Marfil S, Rovirosa C, Puig T, Grau E, Chamorro A, Toledo R, Font M, Palacín D, Lopez-Segui F, Carrillo J, Prat N, Mateu L, Clotet B, Blanco J, Massanella M; VAC-COV-GM-HMAR, KING Cohort Extension and CoronAVI@S studies. Abella E, et al. Among authors: pradenas e. Life Sci Alliance. 2022 Aug 12;5(12):e202201479. doi: 10.26508/lsa.202201479. Life Sci Alliance. 2022. PMID: 35961779 Free PMC article.
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
Pradenas E, Trinité B, Urrea V, Marfil S, Tarrés-Freixas F, Ortiz R, Rovirosa C, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Noguera-Julian M, Carrillo J, Paredes R, Mateu L, Chamorro A, Toledo R, Massanella M, Clotet B, Blanco J. Pradenas E, et al. Cell Rep Med. 2022 Jan 24;3(2):100523. doi: 10.1016/j.xcrm.2022.100523. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233547 Free PMC article.
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
Trinité B, Tarrés-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, Rodríguez de la Concepción ML, Ávila-Nieto C, Aguilar-Gurrieri C, Barajas A, Ortiz R, Paredes R, Mateu L, Valencia A, Guallar V, Ruiz L, Grau E, Massanella M, Puig J, Chamorro A, Izquierdo-Useros N, Segalés J, Clotet B, Carrillo J, Vergara-Alert J, Blanco J. Trinité B, et al. Among authors: pradenas e. Sci Rep. 2021 Jan 28;11(1):2608. doi: 10.1038/s41598-021-81862-9. Sci Rep. 2021. PMID: 33510275 Free PMC article.
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.
Trinité B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarrés-Freixas F, Ortiz R, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Lepore R, Izquierdo-Useros N, Trujillo G, Trapé J, González-Fernández C, Flor A, Pérez-Vidal R, Toledo R, Chamorro A, Paredes R, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Blanco J. Trinité B, et al. Among authors: pradenas e. Viruses. 2021 Jun 12;13(6):1135. doi: 10.3390/v13061135. Viruses. 2021. PMID: 34204754 Free PMC article.
First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain.
Fernández-Bastit L, Rodon J, Pradenas E, Marfil S, Trinité B, Parera M, Roca N, Pou A, Cantero G, Lorca-Oró C, Carrillo J, Izquierdo-Useros N, Clotet B, Noguera-Julián M, Blanco J, Vergara-Alert J, Segalés J. Fernández-Bastit L, et al. Among authors: pradenas e. Viruses. 2021 Dec 16;13(12):2526. doi: 10.3390/v13122526. Viruses. 2021. PMID: 34960795 Free PMC article.
34 results